1. Home
  2. GNSS vs TLSA Comparison

GNSS vs TLSA Comparison

Compare GNSS & TLSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Genasys Inc.

GNSS

Genasys Inc.

HOLD

Current Price

$1.76

Market Cap

101.7M

ML Signal

HOLD

Logo Tiziana Life Sciences Ltd.

TLSA

Tiziana Life Sciences Ltd.

HOLD

Current Price

$1.26

Market Cap

155.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GNSS
TLSA
Founded
1992
2013
Country
United States
United Kingdom
Employees
N/A
N/A
Industry
Consumer Electronics/Appliances
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
101.7M
155.2M
IPO Year
1996
2017

Fundamental Metrics

Financial Performance
Metric
GNSS
TLSA
Price
$1.76
$1.26
Analyst Decision
Strong Buy
Analyst Count
2
0
Target Price
$4.75
N/A
AVG Volume (30 Days)
100.8K
125.2K
Earning Date
05-12-2026
05-06-2025
Dividend Yield
N/A
N/A
EPS Growth
44.44
N/A
EPS
N/A
N/A
Revenue
$26,306,790.00
N/A
Revenue This Year
$80.08
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
29.50
N/A
52 Week Low
$1.46
$0.73
52 Week High
$2.70
$2.60

Technical Indicators

Market Signals
Indicator
GNSS
TLSA
Relative Strength Index (RSI) 39.31 46.09
Support Level $1.72 $1.27
Resistance Level $1.85 $1.59
Average True Range (ATR) 0.08 0.11
MACD 0.00 0.00
Stochastic Oscillator 3.48 36.00

Price Performance

Historical Comparison
GNSS
TLSA

About GNSS Genasys Inc.

Genasys Inc is a provider of Protective Communication solutions, including Genasys Protect software platform and Long Range Acoustic Device (LRAD). Its software platform receives information from variety of sensors and Internet-of-Things (IoT) inputs to collect real-time information on developing and active emergency situations. Genasys uses this information to create and disseminate alerts, warnings, notifications, and instructions through multiple channels before, during, and after public safety and enterprise threats, critical events, and other crisis situations. The Company operates in two business segments: Hardware and Software and its markets are North and South America, Europe, Middle East and Asia. Key revenue is generated from Hardware.

About TLSA Tiziana Life Sciences Ltd.

Tiziana Life Sciences Ltd is a clinical stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. The company's clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, Alzheimer's, and ALS. Its flagship immunotherapeutic candidate, Foralumab (TZLS-401), which is a fully human anti-CD3 monoclonal antibody, is being developed for Non-Active Secondary Progressive Multiple Sclerosis, Alzheimer's and other CNS indications.

Share on Social Networks: